===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1997
Commission file number 0-28454
ANDRX CORPORATION
(Exact name of registrant as specified in its charter)
FLORIDA 65-0366879
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
4001 SOUTHWEST 47TH AVENUE
FORT LAUDERDALE, FL 33314
(Address Of Principal (Zip Code)
Executive Offices)
954-584-0300
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding twelve months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days:
YES [X] NO [ ]
As of April 11, 1997, 13,640,800 shares of the Registrant's only class of common
stock were issued and outstanding.
<PAGE>
ANDRX CORPORATION
INDEX TO THE FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 1997
PAGE NUMBER
-----------
INDEX TO FORM 10-Q 2
PART I FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
Consolidated Balance Sheets
as of March 31, 1997 and
December 31, 1996 3
Consolidated Statements of Operations
for the three months ended
March 31, 1997 and 1996 4
Consolidated Statements of Cash Flows
for the three months ended
March 31, 1997 and 1996 5
Notes to Consolidated Financial Statements 6
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 9
PART II OTHER INFORMATION
Item 1. Legal Proceedings 13
Item 6. Exhibits and Reports on Form 8-K 14
SIGNATURES 15
<PAGE>
<TABLE>
<CAPTION>
ANDRX CORPORATION
PART I
FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
ANDRX CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
Assets MARCH 31, DECEMBER 31,
1997 1996
---------------- -----------------
(UNAUDITED)
<S> <C> <C>
Current assets
Cash and cash equivalents $ 8,789,900 $ 3,427,500
Investments available for sale 17,298,100 26,892,000
Accounts receivable, net of allowances of $1,000,000 (unaudited) and
$969,800 as of March 31, 1997 and December 31, 1996, respectively 15,397,200 13,501,900
Due from joint venture, net 654,300 314,100
Inventories 16,750,500 12,240,400
Prepaid and other current assets 377,700 461,100
---------------- ----------------
Total current assets 59,267,700 56,837,000
Property and equipment, net 12,513,600 9,724,600
Other assets 77,600 74,700
---------------- ----------------
Total assets $ 71,858,900 $ 66,636,300
================ ================
Liabilities and Shareholders' Equity
Current liabilities
Accounts payable $ 21,594,400 $ 13,839,100
Accrued liabilities 3,677,100 3,374,000
Bank loan 3,748,100 6,460,900
Notes payable -- 102,300
Commitment to joint venture, net 143,100 98,400
---------------- ----------------
Total current liabilities 29,162,700 23,874,700
---------------- ----------------
Commitments and contingencies
Shareholders' equity
Convertible preferred stock; $0.001 par value,
1,000,000 shares authorized; no shares issued and
outstanding as of March 31, 1997 (unaudited) and December 31, 1996,
respectively -- --
Common stock; $0.001 par value, 25,000,000 shares
authorized; 13,622,300 (unaudited) and 13,417,500 shares issued
and outstanding as of March 31, 1997 and
December 31, 1996, respectively 13,600 13,400
Additional paid-in capital 58,599,400 57,252,700
Accumulated deficit (15,911,400) (14,508,900)
Unrealized gain (loss) on investments available for sale (5,400) 4,400
---------------- ----------------
Total shareholders' equity 42,696,200 42,761,600
---------------- ----------------
Total liabilities and shareholders' equity $ 71,858,900 $ 66,636,300
================ ================
</TABLE>
See Accompanying Notes to Consolidated Financial Statements.
3
<PAGE>
<TABLE>
<CAPTION>
ANDRX CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
THREE MONTHS ENDED
MARCH 31,
1997 1996
----------------- -----------------
<S> <C> <C>
Revenues
Distribution revenues, net $ 30,662,400 $ 18,039,900
Research and development services
to joint venture 398,500 878,000
--------------- --------------
Total revenues 31,060,900 18,917,900
--------------- --------------
Cost of revenues
Distribution 25,888,600 15,048,800
Research and development services
to joint venture 398,500 878,000
--------------- --------------
Total cost of revenues 26,287,100 15,926,800
--------------- --------------
Gross profit 4,773,800 2,991,100
--------------- --------------
Operating expenses
Selling, general and administrative 3,985,600 2,754,100
Research and development 2,044,400 409,500
Equity in losses of joint venture 403,000 544,500
--------------- --------------
Total operating expenses 6,433,000 3,708,100
--------------- --------------
Loss from operations (1,659,200) (717,000)
Interest expense (130,300) (148,900)
Interest income 387,000 143,500
--------------- --------------
Net loss $ (1,402,500) $ (722,400)
=============== ==============
Net loss per share $ (0.10) $ (0.07)
=============== ==============
Weighted average shares of
common stock outstanding 13,498,900 10,743,600
=============== ==============
</TABLE>
See Accompanying Notes to Consolidated Financial Statements.
4
<PAGE>
<TABLE>
<CAPTION>
ANDRX CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
THREE MONTHS ENDED
MARCH 31,
1997 1996
--------------- ----------------
<S> <C> <C>
Cash flows from operating activities
Net loss $ (1,402,500) $ (722,400)
Adjustments to reconcile net loss to net cash provided by
operating activities
Depreciation and amortization 313,200 203,000
Provision for receivables, net 30,200 87,800
Equity in losses of joint venture 403,000 544,500
Contributions to joint venture (300,000) (705,500)
Increase in accounts receivable (1,925,500) (130,400)
(Increase) decrease in due from joint venture (398,500) 95,600
(Increase) decrease in inventories (4,510,100) 484,700
Decrease in prepaid and other current assets 83,400 28,800
(Increase) decrease in other assets (2,900) 21,600
Increase in accounts payable and accrued liabilities 8,058,400 2,322,600
-------------- --------------
Net cash provided by operating activities 348,700 2,230,300
-------------- --------------
Cash flows from investing activities
Purchase of property and equipment (3,102,200) (824,800)
Maturity of investments available for sale 9,584,100 --
-------------- --------------
Net cash provided by (used in) investing activities 6,481,900 (824,800)
-------------- --------------
Cash flows from financing activities
Net repayments under bank loan (2,712,800) (3,749,000)
Proceeds from exercise of stock options and warrants 1,346,900 --
Payment on notes payable (102,300) (9,900)
-------------- --------------
Net cash used in financing activities (1,468,200) (3,758,900)
-------------- --------------
Net increase (decrease) in cash and cash equivalents 5,362,400 (2,353,400)
Cash and cash equivalents, beginning of period 3,427,500 13,841,400
-------------- --------------
Cash and cash equivalents, end of period $ 8,789,900 $ 11,488,000
============== ==============
Supplemental disclosure of cash paid during the period for:
Interest $ 130,300 $ 148,900
============== ============
</TABLE>
See Accompanying Notes to Consolidated Financial Statements
5
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 1997
(UNAUDITED)
1. GENERAL
In the opinion of management, the accompanying unaudited consolidated
financial statements have been prepared by Andrx Corporation ("Andrx" or the
"Company") pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information and footnote disclosures normally included in
annual financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted pursuant to those rules and
regulations. However, management believes that the disclosures contained herein
are adequate to make the information presented not misleading. The unaudited
consolidated financial statements reflect, in the opinion of management, all
material adjustments (which include only normal recurring adjustments) necessary
to present fairly the Company's financial position and results of operations.
The results of operations and cash flows for the three months ended March 31,
1997, are not necessarily indicative of the results of operations or cash flows
which may be expected for the remainder of 1997. The unaudited consolidated
financial statements should be read in conjunction with the consolidated
financial statements and related notes for the year ended December 31, 1996,
included in the Company's December 31, 1996 Form 10-K.
2. INCOME TAXES
For the three month periods ended March 31, 1997 and 1996, the Company
was not required to provide for federal or state income taxes due to its net
losses. Under the provisions of the Financial Accounting Standards Board
("FASB") Statement of Financial Accounting Standards ("SFAS") No. 109,
"Accounting for Income Taxes", the Company has provided a valuation allowance to
reserve against 100% of its net operating loss carryforwards given the Company's
history of net losses. As of March 31, 1997, for financial reporting purposes
and federal income tax purposes, the Company has net operating loss
carryforwards of approximately $14 million and approximately $11 million,
respectively, which if not utilized, will expire beginning in 2008. Net
operating loss carryforwards are subject to review and possible adjustment by
the Internal Revenue Service and may be limited in the event of certain
cumulative changes in the ownership interest of significant shareholders over a
three-year period in excess of 50%.
6
<PAGE>
3. JOINT VENTURE
Condensed balance sheets and statements of operations for ANCIRC
Pharmaceuticals, the Company's 50/50 joint venture with Watson Pharmaceuticals,
Inc., are as follows:
MARCH 31, 1997 DECEMBER 31, 1996
------------------ -------------------
Cash $ 1,217,000 $ 700,900
Equipment, net 23,500 25,100
----------- -----------
Total assets $ 1,240,500 $ 726,000
=========== ===========
Current liabilities $ 1,768,400 $ 1,047,800
Partners' deficit (527,900) (321,800)
----------- -----------
Total liabilities and
partners' deficit $ 1,240,500 $ 726,000
=========== ===========
THREE MONTHS ENDED
MARCH 31,
1997 1996
-------------- ---------------
Research and development
expenses $ 813,600 $ 1,090,300
============= ==============
Net loss $ (806,100) $ (1,089,000)
============= ==============
As of March 31, 1997 and December 31, 1996, the Company was due
$775,100 and $376,600, respectively, from ANCIRC Pharmaceuticals for research
and development services rendered. In the March 31, 1997 and December 31, 1996
consolidated balance sheets, such amounts due from the joint venture were offset
by $120,800 and $62,500, respectively, representing the amount that Andrx is
required to fund to ANCIRC Pharmaceuticals in order to receive the full amount
due from the joint venture.
4. NET LOSS PER SHARE
For the three months ended March 31, 1997, net loss per share is based
on the weighted average number of common shares outstanding. Since the effect of
common stock equivalents was antidilutive, all such equivalents were excluded in
the calculation of net loss per share.
Pursuant to Securities and Exchange Commission Staff Accounting
Bulletins, common stock and common stock equivalents issued at prices below the
public offering price during the 12-month period prior to the Company's initial
public offering on June 14, 1996, are required to be included in the calculation
of earnings or loss per share, as if they were outstanding for all periods
presented prior to the offering using the treasury stock method. Accordingly,
the
7
<PAGE>
weighted average number of shares of common stock outstanding for three
months ended March 31, 1996 have been adjusted to reflect the impact of such
additional common stock and common stock equivalents issued below the initial
public offering price.
In February 1997, the FASB issued SFAS No. 128, "Earnings Per Share"
("SFAS No. 128"). SFAS No.128 supersedes Accounting Principles Board Opinion No.
15, "Earnings Per Share", and specifies the computation, presentation, and
disclosure requirements for earnings or loss per share ("EPS") for entities with
publicly held common stock or potential common stock. SFAS No. 128 replaces
presentation of primary EPS with a presentation of basic EPS and fully diluted
EPS with diluted EPS. The provisions of SFAS No. 128 require dual presentation
of basic and diluted EPS on the face of the statement of operations for all
entities with complex capital structures. Furthermore, the provisions of SFAS
No.128 require basic EPS and diluted EPS be presented for both income (loss)
from continuing operations and net income (loss) on the face of the statement of
operations. It also requires a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS
computation.
The provisions of SFAS No. 128 are effective for financial statements
for both interim and annual periods ending after December 15, 1997. After
adoption, all prior period EPS data presented shall be restated to conform with
the provisions of SFAS No. 128.
The Company will adopt the provision of SFAS No. 128, as required. The
Company's management does not expect that such adoption will have a material
impact on the Company's EPS calculations.
5. CONTINGENCIES
In January 1996, Hoechst Marion Roussel, Inc. and Carderm Capital, L.P.
(collectively, "Hoechst"), filed suit against the Company claiming patent
infringement as a result of the Company's Abbreviated New Drug Application
("ANDA") filing with the U.S. Food and Drug Administration ("FDA") in late 1995
for a generic version of Cardizem CD (R). The Company responded to these claims
by denying infringement, raising various other defenses and by filing certain
counterclaims against Hoechst. While the Company believes its product does not
infringe upon any of the patents held in connection with the branded product and
that it has meritorious defenses against this suit, the ultimate resolution of
this matter is not currently known and may delay or prevent the Company from
obtaining any approval to market from the FDA related to the ANDA. Although the
Company believes it has adequately provided for such matters based on the
current available information, the Company may incur additional litigation costs
in future years which may be material to the Company's results of operations and
financial position.
8
<PAGE>
ANDRX CORPORATION
PART I
FINANCIAL INFORMATION
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ANDRX CORPORATION AND SUBSIDIARIES ("ANDRX" OR THE "COMPANY") CAUTIONS
READERS THAT CERTAIN IMPORTANT FACTORS MAY AFFECT THE COMPANY'S ACTUAL RESULTS
AND COULD CAUSE SUCH RESULTS TO DIFFER MATERIALLY FROM ANY FORWARD-LOOKING
STATEMENTS WHICH MAY BE DEEMED TO HAVE BEEN MADE IN THIS REPORT OR WHICH ARE
OTHERWISE MADE BY OR ON BEHALF OF THE COMPANY. FOR THIS PURPOSE, ANY STATEMENTS
CONTAINED IN THIS REPORT THAT ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE
DEEMED TO BE FORWARD-LOOKING STATEMENTS. WITHOUT LIMITING THE GENERALITY OF THE
FOREGOING, WORDS SUCH AS "MAY", "WILL", "EXPECT", "BELIEVE", "ANTICIPATE",
"INTEND", "COULD", "WOULD", "ESTIMATE", OR "CONTINUE" OR THE NEGATIVE OTHER
VARIATIONS THEREOF OR COMPARABLE TERMINOLOGY ARE INTENDED TO IDENTIFY
FORWARD-LOOKING STATEMENTS. FACTORS WHICH MAY AFFECT THE COMPANY'S RESULTS
INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS AND UNCERTAINTIES ASSOCIATED WITH A
DRUG DELIVERY COMPANY WHICH HAS NOT COMMERCIALIZED ITS FIRST PRODUCT, INCLUDING
A HISTORY OF NET LOSSES, UNPROVEN TECHNOLOGY, LACK OF MANUFACTURING EXPERIENCE,
CURRENT AND POTENTIAL COMPETITORS WITH SIGNIFICANT TECHNICAL AND MARKETING
RESOURCES, NEED FOR FUTURE CAPITAL AND DEPENDENCE ON COLLABORATIVE PARTNERS AND
ON KEY PERSONNEL. ADDITIONALLY, THE COMPANY IS SUBJECT TO THE RISKS AND
UNCERTAINTIES ASSOCIATED WITH ALL DRUG DELIVERY COMPANIES, INCLUDING COMPLIANCE
WITH GOVERNMENT REGULATIONS AND THE POSSIBILITY OF PATENT INFRINGEMENT
LITIGATION. THE COMPANY IS ALSO SUBJECT TO OTHER RISKS DETAILED HEREIN OR
DETAILED FROM TIME TO TIME IN THE COMPANY'S SECURITIES AND EXCHANGE COMMISSION
FILINGS.
INTRODUCTION
Andrx was organized in August 1992 and, in November 1992, commenced
marketing and distributing generic pharmaceuticals manufactured by third
parties. In February 1993, the Company began to engage in the development of
generic versions of controlled-release oral pharmaceuticals utilizing its
proprietary drug delivery technologies. During 1996, the Company commenced its
efforts on the development of brand name controlled-released products. To date,
the distribution operations have generated substantially all of the Company's
revenues and the Company expects that revenues from the distribution of generic
pharmaceuticals will continue to comprise substantially all of its revenues
until the Company receives final approvals from the U.S. Food and Drug
Administration ("FDA") for the marketing of its products and meaningful revenues
are achieved from a product developed by the Company. The Company expects to
generate negative cash flow and net losses at least through 1997.
To expedite product development and reduce the Company's development
costs, the Company has entered into collaborative agreements with major
pharmaceutical companies. The Company is a 50% partner in the ANCIRC
Pharmaceuticals ("ANCIRC") joint venture with Watson Pharmaceuticals, Inc.
("Watson") for the development of up to eight controlled-release drugs. Capital
contributions to, and net income or losses from, ANCIRC are allocated equally
between the Company and Watson. The Company generates revenues from research and
development services provided to ANCIRC, which services are rendered at cost,
resulting in no gross profit. The Company is also party to development and
licensing agreements for additional controlled-release drugs.
9
<PAGE>
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 1997 AS COMPARED TO THREE MONTHS ENDED
MARCH 31, 1996
TOTAL REVENUES. Total revenues for the three months ended March 31,
1997 ("1997 Quarter") were $31.1 million, an increase of $12.1 million or 64.2%,
as compared to total revenues of $18.9 million for the three months ended March
31, 1996 ("1996 Quarter"). The distribution of generic pharmaceutical products
generated revenues of $30.7 million in the 1997 Quarter, an increase of $12.6
million or 70.0%, as compared to $18.0 million in the 1996 Quarter. The increase
in distribution revenues reflects the Company's greater penetration of the
generic distribution market. Revenues generated by research and development
services to ANCIRC decreased to $399,000 in the 1997 Quarter, as compared to
$878,000 in the 1996 Quarter. This reflects a decrease in the amount of research
and development services provided by Andrx to ANCIRC.
GROSS PROFIT. Gross profit on the distribution of pharmaceutical
products was $4.8 million in the 1997 Quarter, an increase of 59.6% as compared
to $3.0 million in the 1996 Quarter. Gross profit as a percentage of
distribution revenues decreased from 16.6% in the 1996 Quarter to 15.6% in the
1997 Quarter as a result of continuing competition and pricing pressures within
the generic pharmaceutical industry. The Company expects that such factors will
continue to reduce the Company's gross profit percentage in future periods.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Selling, general and
administrative expenses were $4.0 million in the 1997 Quarter, an increase of
$1.2 million or 44.7%, as compared to $2.8 million in the 1996 Quarter. This
increase was primarily attributable to an increase in selling activities to
support the increase in distribution revenues. Selling, general and
administrative expenses were 12.8% of total revenues in the 1997 Quarter, as
compared to 14.6% in the 1996 Quarter.
RESEARCH AND DEVELOPMENT EXPENSES. Research and development expenses
were $2.0 million in the 1997 Quarter, as compared to $410,000 in the 1996
Quarter. The increase in research and development expense reflects the expansion
of development activities for the Company's Abbreviated New Drug Application
("ANDA") and New Drug Application ("NDA") programs. Research and development
expenses for the 1997 Quarter include the operating expenses related to
Company's efforts to establish a commercial-scale manufacturing operation
including the scale-up to commercial size batches of the Company's generic
versions of Cardizem CD(R) and Dilacor XR(R) for which ANDAs were submitted in
late 1995. Research and development expenses exclude cost of revenues for
services rendered to ANCIRC of $399,000 in the 1997 Quarter and $878,000 in the
1996 Quarter.
EQUITY IN LOSSES OF JOINT VENTURE. The Company's equity in losses of
the ANCIRC joint venture was $403,000 in the 1997 Quarter as compared to
$545,000 in the 1996 Quarter. ANCIRC's losses decreased to $806,000 in the 1997
Quarter as compared to $1.1 million in the 1996 Quarter, primarily due to the
decrease in the services rendered by the Company to ANCIRC.
10
<PAGE>
INTEREST EXPENSE. Interest expense was $130,000 in the 1997 Quarter as
compared to $149,000 in the 1996 Quarter. The decrease was primarily the result
of a lower average level of borrowings during the 1997 Quarter. Such borrowings
are utilized to fund the Company's distribution operations. Additionally,
interest expense decreased as the result of amendments to the line of credit
agreement during 1996, whereby, amongst other things, the interest rate on
outstanding borrowings was decreased.
INTEREST INCOME. Interest income was $387,000 in the 1997 Quarter as
compared to $144,000 in the 1996 Quarter. The increase in interest income is the
result of the higher level of cash, cash equivalents and investments available
for sale during the 1997 Quarter as compared to the 1996 Quarter, primarily from
the sale of 2,530,000 shares of the Company's common stock in an Initial Public
Offering ("IPO") in June 1996 for net proceeds of $27.4 million.
INCOME TAXES. For 1996 and 1995, the Company was not required to
provide for federal or state income taxes due to its net losses. As of March 31,
1997, the net operating loss carryforward was approximately $14 million for
financial reporting purposes and approximately $11 million for federal tax
purposes, which, if not utilized, will begin to expire in 2008.
LIQUIDITY AND CAPITAL RESOURCES
In June 1996, the Company consummated the IPO which generated net
proceeds of $27.4 million. Prior thereto, the Company had financed its
operations primarily through private placements of equity securities which
generated proceeds of $27.9 million and, to a lesser extent, through bank
borrowings. As of March 31, 1997, Andrx had $26.1 million in cash, cash
equivalents and investments available for sale and $30.1 million of working
capital.
Net cash provided by operating activities was $349,000 and $2.2 million
in the 1997 Quarter and the 1996 Quarter, respectively. Net cash provided by
operating activities in both quarters was primarily attributable to increases in
accounts payable and accrued liabilities. Such increase in the 1997 Quarter was
offset by the increases in accounts receivable and inventories.
Net cash provided by investing activities was $6.5 million in the 1997
Quarter as compared to net cash used in investing activities of $825,000 in the
1996 Quarter. In the 1997 Quarter, the Company invested $3.1 million in capital
expenditures as compared to $825,000 in the 1996 Quarter. The capital
expenditures in the 1997 Quarter and the 1996 Quarter were primarily for the
procurement of manufacturing equipment and construction of the Company's
commercial-scale manufacturing facility. In the 1997 Quarter, $9.6 million of
investments available for sale matured.
Net cash used in financing activities was $1.5 million and $3.8 million
in the 1997 Quarter and the 1996 Quarter, respectively. Net cash used in
financing activities consisted of net repayments of $2.7 million on the
Company's revolving line of credit in the 1997 Quarter as compared to $3.7
million in the 1996 Quarter. Net cash used in financing activities in the 1997
Quarter was offset by proceeds from the issuance of shares of common stock upon
the exercise of stock options and warrants of $1.3 million.
11
<PAGE>
The Company had an outstanding short-term borrowing balance under its
distribution subsidiary's revolving line of credit of $3.7 million as of March
31, 1997 as compared to $6.5 million as of December 31, 1996. Borrowings under
the line of credit are only available for the financing of the Company's
distribution operations, are secured by all of the assets of that operation and
are subject to a borrowing base related to the value of that operation's
accounts receivable and inventories. The line of credit agreement requires
compliance by the Company with certain covenants including the maintenance of
minimum working capital and net worth levels by the distribution subsidiary. In
October 1996, the Company amended the line of credit agreement whereby, amongst
other things, the interest rate was decreased from the prime rate (8.5% as of
March 31, 1997) plus 1.5% to the prime rate plus 1.0%, and the unused commitment
fee was reduced from .5% to .25%, and under certain circumstances, permitted the
payment of dividends, repayments and advances from the Company's distribution
subsidiary to Andrx and its other subsidiaries.
The Company anticipates that its existing capital resources will be
sufficient to enable it to maintain its operations through the end of 1997. The
Company expects negative cash flows and net losses to continue at least through
1997 because it will use substantial funds for its product development efforts,
including the formulation of and bioequivalence studies for its generic
controlled-release product candidates in the Company's ANDA pipeline, for the
establishment of commercial-scale manufacturing operation and the expanded
development efforts for brand name controlled-release products in the Company's
NDA program. The Company anticipates that during 1997, approximately $12 million
will be used for research and product development activities (including the
Company's share of the funding of the ANCIRC joint venture) and approximately $6
million will be used for capital expenditures, primarily the completion of
commercial-scale manufacturing operations for the commercialization of the
Company's generic versions of Cardizem CD(R) and Dilacor XR(R). After 1997, the
Company may need additional funding in order to complete research and
development for its product candidates and to commercialize these products after
receipt of FDA approvals. Additional funding, whether obtained through public or
private debt or equity financing, or from collaborative arrangements, may not be
available when required or may not be available on terms favorable to the
Company, if at all. If additional financing is not available, the Company may be
required to delay, scale back or eliminate some or all of its research and
development programs or to license to third parties products or technologies
that the Company would otherwise seek to develop itself.
12
<PAGE>
ANDRX CORPORATION
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
As previously reported, in May 1996, an employee of the Company
resigned from his position and, in connection therewith, claimed that he was
entitled to receive, pursuant to the terms of his employment arrangement with
the Company, a royalty equal to 1% of the gross revenues from certain products
under development by the Company. In May 1997, a complaint was filed against the
Company seeking a declaratory judgment as to whether that employee is entitled
to a 1% royalty with respect to Andrx's generic versions of Cardizem CD(R) and
Dilacor XR (R). The Company intends to contest this matter.
There have been no material developments in any other legal matters
since the Company's December 31, 1996 Form 10-K.
13
<PAGE>
ANDRX CORPORATION
PART II
OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
11 Computation of Net Loss Per Share
27 Financial Data Schedule
(b) Reports on Form 8-K:
None
14
<PAGE>
ANDRX CORPORATION
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
By /s/ ALAN P. COHEN
-------------------------------------------
Alan P. Cohen
Chairman and Chief Executive Officer
(Principal Executive Officer)
By /s/ ANGELO C. MALAHIAS
-------------------------------------------
Angelo C. Malahias
Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
May 14, 1997
15
<PAGE>
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
11 Computation of Net Loss Per Share
27 Financial Data Schedule
16
EXHIBIT 11
ANDRX CORPORATION AND SUBSIDIARIES
COMPUTATION OF NET LOSS PER SHARE
(UNAUDITED)
THREE MONTHS ENDED
MARCH 31,
1997 1996
----------------------------
Net loss $ (1,402,500) $ (722,400)
============ ===========
Actual weighted average shares
of common stock outstanding 13,498,900 10,727,100
Impact of options granted within
12 months of initial public offering,
after application of the treasury method -- 16,500
------------ -----------
Weighted average shares of
common stock outstanding 13,498,900 10,743,600
=========== ===========
Net loss per share $ (0.10) $ (0.07)
=========== ===========
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 8,789,900
<SECURITIES> 17,298,100
<RECEIVABLES> 15,397,200
<ALLOWANCES> 1,000,000
<INVENTORY> 16,750,500
<CURRENT-ASSETS> 59,267,700
<PP&E> 12,513,600
<DEPRECIATION> 0
<TOTAL-ASSETS> 71,858,900
<CURRENT-LIABILITIES> 29,162,700
<BONDS> 0
0
0
<COMMON> 13,600
<OTHER-SE> 42,682,600
<TOTAL-LIABILITY-AND-EQUITY> 71,858,900
<SALES> 30,662,400
<TOTAL-REVENUES> 31,060,900
<CGS> 26,287,100
<TOTAL-COSTS> 6,433,000
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 130,300
<INCOME-PRETAX> (1,402,500)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,402,500)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,402,500)
<EPS-PRIMARY> (0.10)
<EPS-DILUTED> 0
</TABLE>
